share_log

4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

4:持股变动声明-高管 Hirawat Samit
美股SEC公告 ·  11/05 17:46

Moomoo AI 已提取核心信息

Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a purchase of 1,830 shares of common stock on November 1, 2024. The transaction was carried out on the open market at a price of $54.675 per share, resulting in a total investment of $100,055.25. Following this transaction, Hirawat's direct holdings in the company increased to 62,109 shares of common stock.
Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a purchase of 1,830 shares of common stock on November 1, 2024. The transaction was carried out on the open market at a price of $54.675 per share, resulting in a total investment of $100,055.25. Following this transaction, Hirawat's direct holdings in the company increased to 62,109 shares of common stock.
施贵宝(BMY)的医疗事务总裁兼药物开发负责人Hirawat于2024年11月1日完成了对1830股普通股的购买。该交易在开放市场以每股54.675美元的价格进行,总投资额达到100,055.25美元。在此交易之后,Hirawat在该公司的直接持股增加到62,109股普通股。
施贵宝(BMY)的医疗事务总裁兼药物开发负责人Hirawat于2024年11月1日完成了对1830股普通股的购买。该交易在开放市场以每股54.675美元的价格进行,总投资额达到100,055.25美元。在此交易之后,Hirawat在该公司的直接持股增加到62,109股普通股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息